Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.

ABSTRACT:

Background

The continued development of targeted therapeutics for cancer treatment has required the concomitant development of more expansive methods for the molecular profiling of the patient's tumor. We describe the validation of the JAX Cancer Treatment Profile™ (JAX-CTP™), a next generation sequencing (NGS)-based molecular diagnostic assay that detects actionable mutations in solid tumors to inform the selection of targeted therapeutics for cancer treatment.

Methods

NGS libraries are generated from DNA extracted from formalin fixed paraffin embedded tumors. Using hybrid capture, the genes of interest are enriched and sequenced on the Illumina HiSeq 2500 or MiSeq sequencers followed by variant detection and functional and clinical annotation for the generation of a clinic

SUBMITTER: Ananda G 

PROVIDER: S-EPMC4481190 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature